At the news
? BULLISHIMPACT 8/10 8-K filed Apr 29, 2026 at 08:30 ET
Chiesi Farmaceutici will acquire KalVista for $27.00 per share in cash, valuing the company at approximately $1.9 billion. The offer represents a 36% premium to the 30-day VWAP, and the transaction is expected to close in Q3 2026, subject to regulatory approvals and minimum tender conditions.
- Offer price: $27.00 per share in cash
- Total equity value: ~$1.9 billion
- 36% premium to 30-day VWAP as of April 28, 2026
- Transaction not subject to financing condition
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access